Physician profile
Robert J Harowitz
NPI 1417942772
$621.07
in general payments reported to CMS, 2019-2025
11 companies · $120 in 2025
The $120 reported for 2025 was more than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.86 · 2020: $14.29 · 2021: $55.14 · 2022: $135 · 2023: $137 · 2024: $104 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $270.83 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $142.24 | 2021-2025 | Entyvio, Eohilia |
| Chiesi USA, INC. | $44.67 | 2022 | |
| Merck Sharp & Dohme LLC | $31.72 | 2023-2024 | Dificid, Bridion |
| Ardelyx, INC. | $26.77 | 2023 | Ibsrela |
| Abbvie INC. | $26.40 | 2019-2021 | |
| Ambu INC. | $17.86 | 2025 | |
| Madrigal Pharmaceuticals | $16.68 | 2025 | Rezdiffra |
| Qol Medical, LLC | $16.55 | 2023 | Sucraid |
| Pacira Pharmaceuticals Incorporated | $14.79 | 2022 | |
| Ferring Pharmaceuticals INC. | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Harowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.